PT - JOURNAL ARTICLE AU - Vlasschaert, Caitlyn AU - Robinson-Cohen, Cassianne AU - Kestenbaum, Bryan AU - Silver, Samuel A. AU - Chen, Jian-Chun AU - Akwo, Elvis AU - Bhatraju, Pavan K AU - Zhang, Ming-Zhi AU - Cao, Shirong AU - Jiang, Ming AU - Wang, Yinqiu AU - Niu, Aolei AU - Siew, Edward AU - Kramer, Holly J AU - Kottgen, Anna AU - Franceschini, Nora AU - Psaty, Bruce M. AU - Tracy, Russell P. AU - Alonso, Alvaro AU - Arking, Dan E. AU - Coresh, Josef AU - Ballantyne, Christie M AU - Boerwinkle, Eric AU - Grams, Morgan AU - Lanktree, Matthew B. AU - Rauh, Michael J. AU - Harris, Raymond C. AU - Bick, Alexander G. TI - Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury AID - 10.1101/2023.05.16.23290051 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.16.23290051 4099 - http://medrxiv.org/content/early/2023/05/17/2023.05.16.23290051.short 4100 - http://medrxiv.org/content/early/2023/05/17/2023.05.16.23290051.full AB - Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes such as DNMT3A, TET2, ASXL1 and JAK2 and the myeloid progeny of these mutated cells contribute to end-organ damage through inflammatory dysregulation. We sought to establish whether CHIP causes acute kidney injury (AKI). To address this question, we first evaluated associations with incident AKI events in three population-based epidemiology cohorts (N = 442,153). We found that CHIP was associated with a greater risk of AKI (adjusted HR 1.26, 95% CI: 1.19–1.34, p<0.0001), which was more pronounced in patients with AKI requiring dialysis (adjusted HR 1.65, 95% CI: 1.24–2.20, p=0.001). The risk was particularly high in the subset of individuals where CHIP was driven by mutations in genes other than DNMT3A (HR: 1.49, 95% CI: 1.37–1.61, p<0.0001). We then examined the association between CHIP and recovery from AKI in the ASSESS-AKI cohort and identified that non-DNMT3A CHIP was more common among those with a non-resolving pattern of injury (HR 2.3, 95% CI: 1.14–4.64, p = 0.03). To gain mechanistic insight, we evaluated the role of Tet2-CHIP to AKI in ischemia-reperfusion injury (IRI) and unilateral ureteral obstruction (UUO) mouse models. In both models, we observed more severe AKI and greater post-AKI kidney fibrosis in Tet2-CHIP mice. Kidney macrophage infiltration was markedly increased in Tet2-CHIP mice and Tet2-CHIP mutant renal macrophages displayed greater pro-inflammatory responses. In summary, this work establishes CHIP as a genetic mechanism conferring risk of AKI and impaired kidney function recovery following AKI via an aberrant inflammatory response in CHIP derived renal macrophages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant #R01DK132155.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to the UK Biobank dataset was provided under application 43397. Local approval for secondary analyses of the data was obtained from the Vanderbilt University Medical Center institutional review board. The Vanderbilt University Medical Centre animal care committee approved all animal study procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online to registered UK Biobank users or upon reasonable request to the authors.